SAN DIEGO, CA, June 12 /PRNewswire-FirstCall/ - Nventa Biopharmaceuticals Corporation announced today the appointment of Sandford D. Smith to its Board of Directors. Mr. Smith is currently President of the International Group and Executive Vice President at Genzyme Corporation. Mr. Smith replaces Ms. Elizabeth Greetham.
Jay M. Short, Ph.D., Chairman of the Board of Directors at Nventa, commented on the appointment: "We are very pleased to welcome Sandy Smith to Nventa's Board. His extensive global experience in the biotechnology field should prove invaluable to us as we grow and continue to guide Nventa through its strategic decisions. I would also like to thank Elizabeth Greetham for her hard work and efforts on the Nventa Board. Over the last five years, Elizabeth's knowledge of the financial and investment communities and the biotechnology field has been a tremendous asset. We will miss her and wish her continued success in all of her future endeavors."
"Sandy has played an integral role in the development of Genzyme as a global organization, one of the most successful biotechnology companies today," said Gregory M. McKee, President and Chief Executive Officer at Nventa. "His wealth of knowledge and experience in developing and commercializing biologics and therapeutics complements the existing talent on the Nventa Board."
Having joined Genzyme in 1996, Mr. Smith is responsible for all of Genzyme's commercial activities outside of the United States. Mr. Smith served as Vice President and General Manager of Genzyme International and President of Genzyme Specialty Therapeutics before being named to his current position in 2006. Prior to joining Genzyme, Mr. Smith was President and Chief Executive Officer at Repligen Corporation. He has served as Vice President of Business Development and Strategic Planning for Bristol-Myers Squibb Company. Mr. Smith has a B.A. from the University of Denver.
Mr. Smith serves as Vice Chairman on the Board of Ariad Pharmaceuticals, Inc. and is on the Board of Directors and Executive Committee of the Boston Philharmonic Orchestra.
About Nventa Biopharmaceuticals Corporation:
--------------------------------------------
Nventa is developing innovative therapeutics for the treatment of viral infections and cancer, with a focus on diseases caused by the human papillomavirus (HPV). The Company is publicly traded on the Toronto Stock Exchange under the symbol NVN. For more information about Nventa Biopharmaceuticals Corporation, please visit the Company's website located at www.nventacorp.com.
CONTACT: Donna Slade, Director, Investor Relations, 9381 Judicial Drive, Suite 180, San Diego, CA, USA, 92121, Dir: (858) 202-4945, dslade@nventacorp.com
Nventa Biopharmaceuticals CorporationCONTACT: Donna Slade, Director, Investor Relations, 9381 Judicial Drive,Suite 180, San Diego, CA, USA, 92121, Dir: (858) 202-4945,dslade@nventacorp.com
